Motunrayo Adisa, MD
Dermatology · Kenilworth, ILNPI 1326229121
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Incyte Corporation accounts for 64.5% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $8,838, more than ten times the $34 reported in 2019.
Across 199 payments — averaging $62.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$8K
- Galderma Laboratories, L.p.$753
- Lilly USA, LLC$647
- Johnson & Johnson$529
- Sanofi$478
- AbbVie$309
- plus $2K from 19 others
What the payments were for
- Consulting fees$6,60053%
- Travel & lodging$1,0378%
- Food & beverage$4,30435%
- Education$4093%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 13 | $7,969 |
| Galderma Laboratories, L.p. | 27 | $753 |
| Lilly USA, LLC | 33 | $647 |
| Johnson & Johnson | 20 | $529 |
| Sanofi | 28 | $478 |
| AbbVie | 14 | $309 |
| Novartis | 8 | $288 |
| Boehringer Ingelheim | 9 | $240 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 8 | $206 |
| Regeneron Healthcare Solutions, Inc. | 6 | $170 |
| Pfizer | 5 | $154 |
| Revance Therapeutics, Inc. | 2 | $123 |
| Sun Pharmaceutical Industries Inc. | 5 | $121 |
| Dermavant Sciences, Inc. | 6 | $116 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $67 |
| Organon | 4 | $36 |
| Genentech USA, Inc. | 1 | $27 |
| Amgen | 1 | $21 |
| LEO Pharma Inc. | 1 | $19 |
| Almirall LLC | 1 | $16 |
| Arcutis Biotherapeutics, Inc. | 1 | $15 |
| Biofrontera Inc. | 2 | $15 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Glenmark Therapeutics Inc. | 1 | $10 |
| Mayne Pharma Commercial LLC | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPZELURA$7,562
How this compares
$12,350 in reported general payments places this provider in the 80th percentile of 606 dermatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 23 | $794 |
| Doxycycline Hyclate | 27 | $550 |
| Triamcinolone Acetonide | 37 | $523 |
| Ketoconazole | 34 | $364 |
| Hydrocortisone | 20 | $165 |
| ValacyclovirValacyclovir Hcl | 12 | $78 |
| Fluconazole | 14 | $49 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Kenilworth
- Ahmad AminNaperville$4.1M
- Raj ChovatiyaChicago$3.6M
- George LewittNorthbrook$3M
- Peter LioChicago$2.4M
- Elizabeth KiracofeChicago$1.6M
- Lana SchmidtEffingham$1.3M
- Melissa AbramsVernon Hills$600K
- Carolyn JacobChicago$566K
- Walter LiszewskiChicago$414K
- Emily RubensteinLincolnshire$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.